Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We would like to congratulate Tariq Khoyratty, who has been appointed as a Celgene Fellow to study the link between neutrophil chromatin organisation in rheumatic patients and their ability to form pathogenic extracellular traps.

Recent evidence suggests an essential contribution of neutrophils in immunity, inflammation and cancer that extend far beyond their well-known anti-microbial responses. This evidence includes their ability to release extracellular DNA structures. The release of extracellular DNA leads to externalizing enhanced levels of putative autoantigens, and is considered to be particularly relevant to neutrophil deleterious roles in rheumatic diseases. This phenomenon is currently collectively referred to as neutrophil extracellular trap (NET) formation.

PAD4 is an enzyme capable of citrullinating proteins that is being considered as an interesting therapeutic target in rheumatic disorders. The primary interest is to determine whether PAD4 inhibition impacts NET formation in human neutrophils in response to disease-relevant stimuli and to determine whether sub-populations of patients are more prone to citrullination-associated NETosis and thus more likely to respond to a PAD4 inhibitor. Mechanistically, NET formation has been linked to a programmed genome disassembly that is precisely organised and sequence programmed at the level of chromatin organisation.

Speaking of the award, Tariq commented “Ultimately, our aim is to define an early signature in peripheral neutrophils that would correlate with disease severity and propensity to form NETs and can easily be detected in human serum or blood.”

Tariq will be based primarily in the Kennedy Institute and work under the supervision of Prof Irina Udalova and Raashid Luqmani

The fellowship starts in November 2017 and runs for 36 months.

Similar stories

Oxford-Bristol Myers Squibb Fellowships awarded to NDORMS researchers

Researchers from the Kennedy Institute of Rheumatology have been awarded fellowships as part of the Oxford-Bristol Myers Squibb Fellowship Programme. Among six researchers from across NDORMS, the programme provides them with an opportunity to gain exposure to the field of commercial drug discovery and development.

Novo Nordisk Postdoctoral Research Fellowship awarded to Inhye Park

Inhye Park has been awarded a Novo Nordisk Postdoctoral Research Fellowship to research the biology of resident vascular macrophages in atherosclerosis.

Researchers from the Kennedy Institute awarded MRC funding

Tonia Vincent, Jelena Bezbradica and Alex Clarke have been awarded funding grants by the Medical Research Council (MRC) for different projects.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS

Doctor Ghada Alsaleh awarded a Versus Arthritis Career Development Fellowship

Postdoctoral Researcher Ghada Alsaleh has been awarded a research grant by Versus Arthritis which she will use to develop a new therapy for osteoarthritis.

EPSRC funds research to avert an antibiotics apocalypse

Researchers at the Kennedy Institute join a collaboration to find new ‘drug-free’ ways of treating illnesses where current treatments have become ineffective due to antibiotic resistance.